Merck KGaA drops $780M to buy biopharma CDMO Exelead, expanding its mRNA reachnews2022-01-06T15:05:17+00:00January 6th, 2022|Fierce Pharma|
Ginkgo, Optimvia team up to boost production of biosynthetic heparinnews2022-01-06T13:29:11+00:00January 6th, 2022|Fierce Pharma|
Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraqnews2022-01-06T13:06:57+00:00January 6th, 2022|Fierce Pharma|
AstraZeneca, Amgen tap Brand Institute in new naming twist for their freshly approved Tezspirenews2022-01-06T09:54:57+00:00January 6th, 2022|Fierce Pharma|
Catalent, still buzzing with pandemic momentum, taps COO Maselli to succeed Chiminski as chief executivenews2022-01-05T15:51:25+00:00January 5th, 2022|Fierce Pharma|
Blueprint’s Albers hands CEO baton to deal mastermind Haviland after steering 2 cancer drug launchesnews2022-01-05T15:48:43+00:00January 5th, 2022|Fierce Pharma|
FDA, working through pandemic backlog, pauses US factory inspections on omicron concernsnews2022-01-05T14:23:18+00:00January 5th, 2022|Fierce Pharma|
FDA posts trio of voluntary recalls on treatments for heart disease, diabetes and dermatitisnews2022-01-05T14:03:27+00:00January 5th, 2022|Fierce Pharma|
Merck, Pfizer, Lilly and J&J restored funding to legislators who stoked Jan. 6 Capitol attack, watchdog saysnews2022-01-05T05:40:03+00:00January 5th, 2022|Fierce Pharma|
Pfizer carries pandemic momentum into 2022, scoring another huge Paxlovid deal with the USnews2022-01-04T17:56:27+00:00January 4th, 2022|Fierce Pharma|
